HKCL Introduction

Hong Kong Cyclotron Laboratories Limited (HKCL) is a Hong Kong–based radiopharmaceuticals manufacturer with over 15+ years of PET drug production and distribution experience serving hospitals, clinics, and imaging centers across the territory. The company specializes in Fluorodeoxyglucose (18F-FDG), Prostate-Specific Membrane Antigen (18F-PSMA & 68Ga-PSMA), 18F-Flutemetamol (18F-FMM), 68Ga-DOTATATE and 11C-Acetate, and other advanced PET tracers, operating Hong Kong’s first non‑hospital cyclotron facility and maintaining a leading, territory‑wide delivery network.

Who We Are

HKCL is the healthcare subsidiary of Asia Allied Infrastructure Holdings Limited (stock code: 00711.HK), aligning radiopharmaceutical manufacturing with a diversified infrastructure and healthcare group strategy. Established in 2006 and headquartered at Hong Kong Science Park, the company focuses on PET radiopharmaceuticals for clinical imaging, notably FDG. Together with its subsidiary, HKCL supports a city‑wide PET radiopharmacy distribution network supplying public and private hospitals, and imaging centers.

Experience and Milestones

With 15 Years+ of continuous PET drug production, HKCL has built robust cGMP operations and a dependable supply chain tailored to time‑critical imaging needs.

Milestones include Hong Kong’s first non‑hospital cyclotron facility and the city’s first Medium‑Energy Cyclotron, expanding capacity and isotopes versatility. HKCL also implemented the China region’s first fully automatic Comecer dispenser for hands‑free aseptic dispensing, further enhancing sterility assurance and operator safety.